Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome

Current Opinion in Investigational Drugs

Volumn 5, Issue 3, 2004, Pages 283-289

  Harwood Jr , H James ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Acetyl CoA carboxylase; Enzyme inhibition; Fatty acid oxidation; Fatty acid synthesis; Metabolic regulation; Metabolic syndrome

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ENZYME INHIBITOR; FATTY ACID; ISOENZYME; MALONYL COENZYME A;

ANIMAL; DRUG ANTAGONISM; HUMAN; METABOLIC SYNDROME X; METABOLISM; REVIEW;

ACETYL-COA CARBOXYLASE; ANIMALS; ENZYME INHIBITORS; FATTY ACIDS; HUMANS; ISOENZYMES; MALONYL COENZYME A; METABOLIC SYNDROME X;

EID: 3042619469     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Reaven GM: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 37(12):1595-1607.
2. Howard BV: Epidemiology of the plurimetabolic syndrome. In: Atherosclerosis X. Woodford FP, Davignon J, Sniderman A (Eds), Elsevier Science BV, New York, NY, USA (1995):516-519.
3. Crepaldi G: Pleurimetabolic syndrome or syndrome X: An overview. In: Atherosclerosis X. Woodford FP, Davignon J, Sniderman A (Eds), Elsevier Science BV, New York, NY, USA (1995):511-515.
4. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. J Am Med Assoc (2002) 287(3):356-359.
5. National Cholesterol Education Program Expert Panel: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc (2001) 285(19):2486-2497.
6. Alberti KGMM, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med (1998) 15(7):539-553.
7. Moller DE: New drug targets for type-2 diabetes and the metabolic syndrome. Nature (2001) 414(6865):821-827.
8. Grundy SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol (1999) 83(9B):25F-29F.
9. Haffner S-M, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP: Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes (1992) 41(6):715-722.
10. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care (2001) 24(4):683-689.
11. Trevisan M, Liu J, Bahsas FB, Menotti A: Syndrome X and mortality: A population-based study. Risk factor and life expectancy research group. Am J Epidemiol (1998) 148(10):958-966.
12. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: The metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 108(4):414-419.
13. Mudaliar S, Henry R, Helwick CA: Diabetes and cardiovascular disease. Endocrinology (2003) 13:S1-S2.
14. Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care (2003) 26(Suppl 1):S83-S86.
15. Arauz-Pacheco C, Parrott MA, Raskin P: Treatment of hypertension in adults with diabetes. Diabetes Care (2003) 26(Suppl 1):S80-S82.
16. Colwell JA: Aspirin therapy in diabetes. Diabetes Care (2003) 26(Suppl 1):S87-S88.
17. Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J, Ganiats TG, Ginsberg H, Kahn R, Nwankwo R, Rewers M et al: The prevention or delay of type-2 diabetes. Diabetes Care (2003) 26(Suppl 1):S62-S69.
18. Bjorntorp P: Fatty acids, hyperinsulinemia, and insulin resistance: Which comes first? Curr Opin Lipidol (1994) 5(3):166-174.
19. Despres JP, Marette A: Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol (1994) 5(4):274-289.
20. McGarry JD: What if Minkowski had been ageusic? An alternative angle on diabetes. Science (1992) 258(5083):766-770.
21. Bergman RN, van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP, Ellmerer M: Central role of the adipocyte in the metabolic syndrome. J Invest Med (2001) 49(1):119-126.
22. Kim KH: Regulation of mammalian acetyl-CoA carboxylase. Annu Rev Nutr (1997) 17:77-99.
23. 2+-dependent phosphatase. J Biol Chem (1985) 260(10):6318-6323.
24. Hashimoto T, Numa S: Kinetic studies on the reaction mechanism and the citrate activation of liver acetyl-CoA carboxylase. Eur J Biochem (1971) 18(3):319-331.
25. Beaty NB, Lane MD: Acetyl-CoA carboxylase. Rapid purification of the chick liver enzyme and steady state kinetic analysis of the carboxylase- catalyzed reaction. J Biol Chem (1982) 257(2):924-929.
26. Zhang H, Yang Z, Shen Y, Tong L: Crystal structure of the carboxyltransferase domain of acetyl-CoA carboxylase. Science (2003) 299(5615):2064-2067.
27. McGarry JD, Foster DW: Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem (1980) 49:395-420.
28. Munday MR, Hemingway CJ: The regulation of acetyl-CoA carboxylase - potential target for the action of hypolipidemic agents. Adv Enzyme Regul (1999) 39:205-234.
29. Allred JB, Reilly KE: Short-term regulation of acetyl-CoA carboxylase in tissues of higher animals. Prog Lipid Res (1996) 35(4):371-385.
30. Abu-Elheiga L, Oh W, Kordari P, Wakil SJ: Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high fat/high carbohydrate diets. Proc Natl Acad Sci USA (2003) 100(18):10207-10212.
31. Trumble GE, Smith MA, Winder WW: Purification and characterization of rat skeletal muscle acetyl-CoA carboxylase. Eur J Biochem (1995) 231(1):192-198.
32. Ogiwara H, Tanabe T, Nikawa J, Numa S: Inhibition of rat liver acetyl-CoA carboxylase by palmitoyl-CoA. Formation of equimolar enzyme-inhibitor complex. Eur J Biochem (1978) 89(1):33-41.
33. Brun T, Roche E, Assimacopoulos-Jeannet F, Corkey BE, Kim KH, Prentki M: Evidence for an anaplerotic/malonyl-CoA pathway in pancreatic β-cell signaling. Diabetes (1996) 45(2):190-198.
34. McGarry JD, Woeltje KF, Kuwajima M, Foster DW: Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes Metab Rev (1989) 5(3):271-284.
35. McGarry JD, Brown NF: The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem (1997) 244(1):1-14.
36. Buckley MG, Rath EA: Regulation of fatty acid synthesis and malonyl-CoA content in mouse brown adipose tissue in response to cold-exposure, starvation or re-feeding. Biochem J (1987) 243(2):437-442.
37. Saha A, Kurowski TG, Ruderman NB: A malonyl-CoA fuel-sensing mechanism in muscle: Effects of insulin, glucose, and denervation. Am J Physiol - Endocrinol Metab (1995) 269(2 Pt 1):E283-E289.
38. Rasmussen BB, Holmback UC, Volpi E, Morio-Liondore B, Paddon-Jones D, Wolfe RR: Malonyl-CoA and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle. J Clin Invest (2002) 110(11):1687-1693.
39. Hu Z, Cha SH, Chohnan S, Lane MD: Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc Natl Acad Sci USA (2003) 100(22):12624-12629.
40. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP: C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci USA (2002) 99(14):9498-9502.
41. Chen S, Ogawa A, Ohneda M, Unger RH, Foster DW, McGarry JD: More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase-1 interaction as a key event in pancreatic β-cell signaling. Diabetes (1994) 43(7):878-883.
42. Bianchi A, Evans JL, Iverson AJ, Nordlund AC, Watts TD, Witters LA: Identification of an isozymic form of acetyl-CoA carboxylase. J Biol Chem (1990) 265(3):1502-1509.
43. Iverson AJ, Bianchi A, Nordlund AC, Witters LA: Immunological analysis of acetyl-CoA carboxylase mass, tissue distribution, and subunit composition. Biochem J (1990) 269(2):365-371.
44. Widmer J, Fassihi KS, Schlichter SC, Wheeler KS, Crute BE, King N, Nutile-McMenemy N, Noll WW, Daniel S, Ha J, Kim KH et al: Identification of a second human acetyl-CoA carboxylase gene. Biochem J (1996) 316(3):915-922.
45. Ha J, Lee JK, Kim KS, Witters LA, Kim KH: Cloning of human acetyl-CoA carboxylase-β and its unique features. Proc Natl Acad Sci USA (1996) 93(21):11466-11470.
46. Abu-Elheiga L, Almarza-Ortega DB, Baldini A, Wakil SJ: Human acetyl-CoA carboxylase 2. Molecular cloning, characterization, chromosomal mapping, and evidence of two isoforms. J Biol Chem (1997) 272(16):10669-10677.
47. Abu-Elheiga L, Matzuk MM, Abo-Hashema KAH, Wakil SJ: Continuous fatty acid oxidation and reduced fat storage in mice lacking acetylCoA carboxylase 2. Science (2001) 291(5513):2613-2616.
48. Abu-Elheiga L, Brinkley WR, Zhong L, Chirala SS, Woldegiorgis G, Wakil SJ: The subcellular localization of acetyl-CoA carboxylase 2. Proc Natl Acad Sci USA (2000) 97(4):1444-1449.
49. McCune SA, Harris RA: Mech anism responsible for 5(tetradecyloxy)-2- furoic acid inhibition of hepatic lipogenesis. J Biol Chem (1979) 254(20):10095-10101.
50. Arbeeny CM, Meyers DS, Bergquist KE, Gregg RE: Inhibition of fatty acid synthesis decreases very low density lipoprotein secretion in the hamster. J Lipid Res (1992) 33(6):843-851.
51. Parker RA, Kariya T, Grisar JM, Petrow V: 5-(Tetradecyloxy)-2- furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids. J Med Chem(1977) 20(6):781-791.
52. Fukuda N, Ontko JA: Interactions between fatty acid synthesis, oxidation, and esterification in the production of triglyceride-rich lipoproteins by the liver. J Lipid Res (1984) 25(8):831-842.
53. Kempen HJ, Imbach AP, Giller T, Neumann WJ, Hennes U, Nakada N: Secretion of ApoA1 and ApoB by HepG2 cells: Regulation by substrates and metabolic inhibitors. J Lipid Res (1996) 36(8):1796-1806.
54. Triscari J, Sullivan AC: Anti-obesity activity of a novel lipid synthesis inhibitor. Int J Obesity (1984) 8(Suppl 1):227-239.
55. Harwood HJ Jr, Petras SF, Shelly LD, Zaccaro LM, Perry DA, Makowski MR, Hargrove DM, Martin KA, Tracey WR, Chapman JG, Magee WP et al: Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem (2003) 278(39):37099-37111.
56. Harwood HJ Jr, Petras SF, Shelly LD, Soliman VF, Perry DA: AcetylCoA carboxylase inhibition by CP-640186 reduces liver, muscle and adipose tissue fat content, reduces body weight and percentage body fat, and improves insulin sensitivity in rats with diet-induced metabolic syndrome. (2004):manuscript in preparation.
57. Vahlensieck HF, Pridzun L, Reichenbach H, Hinnen A: Identification of the yeast ACC1 gene product (acetyl-CoA carboxylase) as the target of the polyketide fungicide soraphen A. Curr Genet (1994) 25(2):95-100.
58. Levert KL, Waldrop GL: A bisubstrate analog inhibitor of the carboxyltransferase component of acetyl-CoA carboxylase. Biochem Biophys Res Commun (2002) 291(5):1213-1217.
59. Levert KL, Waldrop GL, Stephens JM: A biotin analog inhibits acetyl-CoA carboxylase activity and adipogenesis. J Biol Chem(2002) 277(19):16347-16350.
60. Gronwald JW: Herbicides inhibiting acetyl-CoA carboxylase. Biochem Soc Trans (1994) 22(3):616-621.
61. Seng TW, Skillman TR, Yang N, Hammond C: Cyclohexanedione herbicides are inhibitors of rat heart acetyl-CoA carboxylase. Bioorg Med Chem Lett (2003) 13(19):3237-3242.
62. Balkau R, Charles MA: Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabetic Med (1999) 16(5):442-443.
63. Treadway JL, McPherson RK, Petras SF, Shelly LD, Frederick KS, Sagawa K, Perry DA, Harwood HJ Jr: Effect of the acetyl-CoA carboxylase inhibitor CP-346086 on glycemic control in diabetic ob/ob mice. Diabetes (2004):manuscript submitted.
64. PFIZER INC (Perry DA, Harwood HJ Jr): Acetyl-CoA carboxylase inhibitors. WO-03072197 (2003).
65. HOFFMANN-LA ROCHE AG (Gubler M, Mizrahi J): Use of soraphen derivatives. WO-03011867 (2003).
66. UNIVERSITY OF LOUISIANA (Waldrop GL, Stephens JM, Levert KL): Inhibition of the carboxyltransferase component of acetyl-CoA carboxylase and the use of such inhibition in anti-cancer and antilipogenic therapies. US-06485941 (2002).
67. FUJIREBIO INC (Ikawa H, Nishimura M, Okada K, Nakamura T): Butanoic acid amide derivative. JP-11171847 (1999).
68. FUJIREBIO INC (Ikawa H, Nishimura M, Okada K, Nakamura T): Aromatic amide derivative. JP-11171848 (1999).
69. AJINOMOTO CO INC (Ikawa H, Nishimura M, Okada K, Nakamura T, Inaba J, Kojima K, Kosono H): Hypoglycemics. WO-00202101 (2002).
70. AJINOMOTO CO INC (Maezono K, Ishida N, Ohsumi K, Kondo N): Drugs against obesity and drugs against fatty liver. WO-03057255 (2003).
71. A2JINOMOTO CO INC (Suzuki N, Nihei Y, Ichinose H, Hatanaka T, Maezono K, Ohsumi K, Kondo N): N-alkylsulfonyl- substituted amide derivatives. WO-03059871 (2003).
72. AJINOMOTO CO INC (Suzuki N, Nihei Y, Ichinose H, Hatanaka T, Maezono K, Ohsumi K, Kondo N, Yamamoto T, Nakanishi E): Acyl sulfonamide derivative. WO-03059886 (2003).
73. AJINOMOTO CO INC (Ikawa H, Nishimura M, Okada K, Nakamura T, Kojima K, Kosono H): Acylsulfonamide derivative. WO-00202517 (2002).